CXCR2 and ovarian cancer: The most extensively studied CXCR2 inhibitor is SB225002: (N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea) [181], which exhibits antitumor activity against cervical cancer [107], ovarian cancer [196], and androgen-independent prostate cancer [180].